Not found

Peter Zage,

Houston Methodist


Areas Of Expertise

Neuroblastoma Retinoblastoma Developmental therapeutics
Publications

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma
Whittle, SB, Patel, K, Zhang, L, Woodfield, SE, du, M, Smith, V & Zage, PE 2016, Investigational New Drugs, pp. 1-8. DOI:

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
Du, M, Zhang, L, Scorsone, KA, Woodfield, SE & Zage, PE 2016, Scientific Reports, vol 6, 27458. DOI:

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Woodfield, SE, Zhang, L, Scorsone, KA, Liu, Y & Zage, PE 2016, BMC Cancer, vol 16, no. 1, 172. DOI:

A polymorphism in the FGFR4 gene is associated with risk of neuroblastoma and altered receptor degradation
Whittle, SB, Reyes, S, Du, M, Gireud, M, Zhang, L, Woodfield, SE, Ittmann, M, Scheurer, ME, Bean, AJ & Zage, PE 2016, Journal of Pediatric Hematology/Oncology, vol 38, no. 2, pp. 131-138. DOI:

Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
Zhang, L, Scorsone, K, Woodfield, SE & Zage, PE 2015, Cancer Chemotherapy and Pharmacology, vol 76, no. 5, pp. 977-987. DOI:

CD114 expression mediates melanoma tumor cell growth and treatment resistance
Zhang, L, Agarwal, S, Shohet, JM & Zage, PE 2015, Anticancer Research, vol 35, no. 7, pp. 3787-3792.

MTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
Zhang, H, Dou, J, Yu, Y, Zhao, Y, Fan, Y, Cheng, J, Xu, X, Liu, W, Guan, S, Chen, Z, Shi, Y, Patel, R, Vasudevan, SA, Zage, PE, Zhang, H, Nuchtern, JG, Kim, ES, Fu, S & Yang, J 2015, Apoptosis, vol 20, no. 1, pp. 50-62. DOI:

The novel kinase inhibitor EMD1214063 is effective against neuroblastoma
Scorsone, K, Zhang, L, Woodfield, SE, Hicks, J & Zage, PE 2014, Investigational new drugs, vol 32, no. 5, pp. 815-824. DOI:

Congenital neuroblastoma in a neonate with isotretinoin embryopathy
Aguilar, S, Louis, C, Hicks, J, Zage, P & Russell, H 2014, Journal of Pediatric Hematology/Oncology, vol 36, no. 2. DOI:

UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation
Sirisaengtaksin, N, Gireud, M, Yan, Q, Kubota, Y, Meza, D, Waymire, JC, Zage, PE & Bean, AJ 2014, Journal of Biological Chemistry, vol 289, no. 5, pp. 3026-3039. DOI:

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system
Stricker, TP, Morales La Madrid, A, Chlenski, A, Guerrero, L, Salwen, HR, Gosiengfiao, Y, Perlman, EJ, Furman, W, Bahrami, A, Shohet, JM, Zage, PE, Hicks, MJ, Shimada, H, Suganuma, R, Park, JR, So, S, London, WB, Pytel, P, Maclean, KH & Cohn, SL 2014, Molecular Oncology, vol 8, no. 3, pp. 669-678. DOI:

Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies
Brown, BS, Patanam, T, Mobli, K, Celia, C, Zage, PE, Bean, AJ & Tasciotti, E 2014, Cancer Biology and Therapy, vol 15, no. 7, pp. 851-861. DOI:

UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors
Zage, PE, Sirisaengtaksin, N, Liu, Y, Gireud, M, Brown, BS, Palla, S, Richards, KN, Hughes, DPM & Bean, AJ 2013, Cancer, vol 119, no. 4, pp. 915-923. DOI:

New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
Zage, PE, Louis, CU & Cohn, SL 2012, Pediatric Blood and Cancer, vol 58, no. 7, pp. 1099-1105. DOI:

Notch pathway activation induces neuroblastoma tumor cell growth arrest
Zage, PE, Nolo, R, Fang, W, Stewart, J, Garcia-Manero, G & Zweidler-Mckay, PA 2012, Pediatric Blood and Cancer, vol 58, no. 5, pp. 682-689. DOI:

Growth factor receptor trafficking as a potential therapeutic target in pediatric cancer
Zage, PE & Bean, AJ 2012, Frontiers in Biology, vol 7, no. 1, pp. 1-13. DOI:

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma
Levy, AG, Zage, PE, Akers, LJ, Ghisoli, ML, Chen, Z, Fang, W, Kannan, S, Graham, T, Zeng, L, Franklin, AR, Huang, P & Zweidler-McKay, PA 2012, Investigational New Drugs, vol 30, no. 1, pp. 191-199. DOI:

Treatment of recurrent diffuse intrinsic pontine glioma: The MD Anderson Cancer Center experience
Wolff, JE, Rytting, ME, Vats, TS, Zage, PE, Ater, JL, Woo, S, Kuttesch, J, Ketonen, L & Mahajan, A 2012, Journal of Neuro-Oncology, vol 106, no. 2, pp. 391-397. DOI:

Primary mediastinal neoplasms
Benveniste, MFK, Zage, PE & Erasmus, JJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, pp. 63-78. DOI:

Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF ß-TRCP in neuroblastoma cells
Singh, A, Rokes, C, Gireud, M, Fletcher, S, Baumgartner, J, Fuller, G, Stewart, J, Zage, P & Gopalakrishnan, V 2011, Cancer, vol 117, no. 22, pp. 5189-5202. DOI: